Affinage

PAX4

Paired box protein Pax-4 · UniProt O43316

Length
350 aa
Mass
37.8 kDa
Annotated
2026-04-29
100 papers in source corpus 35 papers cited in narrative 35 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PAX4 is a paired-domain/homeodomain transcription factor that functions primarily as a transcriptional repressor to direct pancreatic endocrine progenitors toward the beta- and delta-cell lineages while suppressing alpha-cell fate. It represses glucagon, insulin, ghrelin, and IAPP promoters through multiple repression domains in the homeodomain and C-terminus, and engages in mutual cross-repression with the alpha-cell specifier Arx to allocate endocrine cell fates—loss of both factors defaults all endocrine cells to a delta-cell identity (PMID:9121556, PMID:14561778, PMID:15930104, PMID:18058910). In adult beta cells, PAX4 promotes survival by upregulating Bcl-xL and Bcl-2, suppresses ER stress-induced apoptosis, drives proliferation through c-myc and Cdk4, and its ectopic expression in alpha or delta cells is sufficient to convert them into functional beta-like cells capable of reversing chemically induced diabetes (PMID:15596543, PMID:19665969, PMID:26813254, PMID:29025873). Homozygous PAX4 loss-of-function variants cause transient neonatal diabetes in humans, and multiple missense mutations (R129W, R133W, R164W, R192H) that impair its repressor activity are linked to MODY9 and ketosis-prone diabetes (PMID:40614820, PMID:17426099, PMID:15509590, PMID:22521316).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1997 High

    The foundational question of what Pax4 does in the organism was answered: it is essential for differentiation of beta and delta cells, as its absence causes complete loss of these lineages with compensatory expansion of alpha cells.

    Evidence Homologous recombination knockout in mice with immunohistochemistry and hormone expression analysis

    PMID:9121556

    Open questions at the time
    • Mechanism of lineage redirection unknown
    • Direct transcriptional targets unidentified
    • Whether Pax4 acts as activator or repressor not resolved
  2. 1999 High

    PAX4 was established as a transcriptional repressor rather than activator: it binds bipartite paired-domain/homeodomain DNA motifs and represses glucagon and insulin promoters through portable repression domains, with a cryptic activation domain active only in specific cellular contexts.

    Evidence SELEX-like binding selection, GAL4 fusion reporter assays, domain deletion mapping in alpha- and beta-cell lines, E1A co-expression rescue

    PMID:10364449 PMID:10567552 PMID:10567553 PMID:10601637

    Open questions at the time
    • In vivo direct target genes not mapped genome-wide
    • Mechanism of repression (co-repressor recruitment vs. competition with PAX6) not resolved
    • Post-translational modifications regulating repressor/activator switch uncharacterized
  3. 2000 High

    Upstream regulation of PAX4 expression was defined: HNF1alpha and Neurogenin3 synergistically activate the PAX4 promoter through a conserved 118-bp element, and PAX4 exerts strong negative autoregulation by binding its own promoter, establishing the transcriptional cascade linking endocrine progenitor specification to PAX4 induction.

    Evidence Promoter deletion mapping with in vivo transgenic validation, site-directed mutagenesis, co-immunoprecipitation of HNF1alpha–Ngn3 interaction, endogenous gene induction assays

    PMID:10967107 PMID:11118882 PMID:12837760

    Open questions at the time
    • Chromatin-level regulation and epigenetic marks at the PAX4 locus not examined
    • Whether NRSF-mediated repression operates in endocrine progenitors in vivo remains untested
  4. 2003 High

    The cross-antagonism between Arx and Pax4 was uncovered as the core mechanism allocating endocrine fate: Arx loss mirrors the inverse of Pax4 loss, and each factor's transcripts accumulate in the other's knockout, establishing mutual transcriptional repression as the binary switch between alpha- and beta-cell identity.

    Evidence Reciprocal gene targeting knockouts in mice with immunohistochemistry and RT-PCR

    PMID:14561778

    Open questions at the time
    • Whether Pax4 directly binds the Arx locus or acts indirectly was unknown
    • Delta-cell fate in combined loss not yet determined
  5. 2005 High

    The double knockout of Arx and Pax4 revealed that delta-cell identity is the default endocrine state: in their combined absence, virtually all endocrine cells adopt a somatostatin-producing fate, establishing the hierarchical logic of the Arx/Pax4 system.

    Evidence Arx/Pax4 double knockout mice with immunohistochemistry and qRT-PCR

    PMID:15930104

    Open questions at the time
    • What specifies the delta-cell default program remains unclear
    • Whether this hierarchy is conserved in humans untested
  6. 2004 High

    PAX4's role in adult beta cells was expanded beyond development: overexpression in rat and human islets stimulated beta-cell proliferation 3.5-fold and identified Bcl-xL and c-myc as direct transcriptional targets, linking PAX4 to survival and growth pathways.

    Evidence Adenoviral overexpression in isolated rat and human islets, promoter-reporter assays, proliferation assays, calcium and ATP measurements

    PMID:15596543

    Open questions at the time
    • Whether endogenous PAX4 levels in adult beta cells are sufficient for these effects
    • Whether Bcl-xL is a direct binding target or indirect remained uncertain
  7. 2007 Medium

    Loss-of-function studies confirmed the survival role: shRNA knockdown of Pax4 reduced Bcl-xL by ~50% and doubled spontaneous apoptosis, while disease-associated PAX4 variants (R164W, R133W) showed impaired repressor activity, providing a functional mechanism for MODY and ketosis-prone diabetes associations.

    Evidence shRNA knockdown in INS-1E cells with apoptosis assays; luciferase reporter assays of mutant PAX4 proteins on insulin/glucagon promoters

    PMID:15509590 PMID:17260022 PMID:17426099

    Open questions at the time
    • No chromatin occupancy data for disease-linked mutants
    • Whether impaired repression alone is sufficient for disease phenotype in vivo
    • Reporter assays are in single labs
  8. 2008 High

    Ghrelin was identified as a repressed target of Pax4: Pax4-deficient mice showed overabundant ghrelin-expressing epsilon cells in pancreas and duodenum, extending Pax4's role to suppression of the epsilon-cell fate.

    Evidence Pax4 knockout mice with lineage tracing and in vitro reporter assays

    PMID:18058910

    Open questions at the time
    • Direct binding to ghrelin regulatory elements not shown in mammals at this point
    • Functional significance of ghrelin derepression for islet physiology unclear
  9. 2009 High

    A landmark cell-conversion study showed that ectopic Pax4 in alpha cells forces beta-cell conversion, triggers compensatory alpha-cell neogenesis via Ngn3 re-expression, and the resulting continuous alpha-to-beta conversion expands beta-cell mass sufficiently to reverse streptozotocin-induced diabetes.

    Evidence Conditional transgenic Pax4 expression in alpha cells with lineage tracing and STZ-induced diabetes model in mice

    PMID:19665969

    Open questions at the time
    • Whether converted cells are functionally equivalent to native beta cells long-term
    • Translational applicability to human alpha cells undemonstrated
    • Mechanism of Ngn3 re-activation in ducts not resolved
  10. 2011 High

    The cytoprotective mechanism was refined: Pax4 suppresses NF-κB target genes (IL-1β), increases Bcl-2, and promotes dedifferentiation/proliferation through MafA repression and Cdk4/c-myc induction; the diabetes-linked R129W mutant fails to protect and instead increases NOS2 and IL-1β.

    Evidence Conditional beta-cell Pax4 overexpression in transgenic mice challenged with STZ, cytokine-treated islets, qRT-PCR, cytochrome C release assay

    PMID:21521872

    Open questions at the time
    • Direct binding to NF-κB target promoters not shown
    • Whether MafA repression is direct or indirect unclear
  11. 2012 High

    The Pax4/Arx antagonism was extended beyond the pancreas to intestinal enteroendocrine subtype specification, with Pax4 promoting serotonin and somatostatin cell fates while suppressing L-cell (GLP-1) differentiation.

    Evidence Pax4 and Arx knockout mice analyzed in intestine and colon with immunohistochemistry and lineage tracing

    PMID:22570716

    Open questions at the time
    • Direct transcriptional targets in gut endocrine cells not identified
    • Whether the mechanism is identical to pancreatic antagonism or uses distinct targets
  12. 2015 High

    Delta-to-beta conversion was demonstrated: ectopic Pax4 in somatostatin-producing delta cells converts them to functional beta-like cells, triggering compensatory neogenesis and partial diabetes reversal, expanding the convertible cell types beyond alpha cells.

    Evidence SST-Cre-driven conditional Pax4 expression in transgenic mice with lineage tracing and STZ diabetes model

    PMID:29025873

    Open questions at the time
    • Efficiency of delta-to-beta conversion not quantified relative to alpha-to-beta
    • Mechanism by which Pax4 overrides delta-cell identity at the chromatin level unknown
  13. 2016 High

    PAX4 was shown to protect beta cells from ER stress by preserving ER homeostasis, rescuing ER luminal swelling, and maintaining glucose-stimulated calcium oscillations, while transcriptomic profiling identified ER homeostasis and cell-cycle gene networks as PAX4-regulated.

    Evidence Conditional transgenic overexpression, thapsigargin ER stress induction, electron microscopy, calcium imaging, microarray profiling

    PMID:26813254

    Open questions at the time
    • Which ER homeostasis genes are direct binding targets not resolved
    • Whether ER protection is independent of or downstream of Bcl-xL induction unclear
  14. 2023 High

    Genome-wide direct target mapping in human beta cells (CUT&RUN-seq) identified PAX4-bound genes involved in islet development and glucose-stimulated insulin secretion; PAX4 knockdown or deletion in human cells caused derepression of alpha-cell genes and reduced insulin content, while risk alleles in hiPSCs increased polyhormonal cells reversible by gene correction.

    Evidence CUT&RUN-sequencing in EndoC-βH1, CRISPR deletion in hiPSCs, RNA-seq, insulin secretion assays, gene correction

    PMID:37777536

    Open questions at the time
    • CUT&RUN targets not fully validated by individual promoter assays
    • Whether PAX4 occupancy differs between fetal and adult beta cells unknown
  15. 2025 High

    Homozygous PAX4 loss-of-function was shown to cause transient neonatal diabetes in humans—unlike the permanent beta-cell absence in mice—revealing species differences in PAX4 requirement for beta-cell development; additionally, proteasomal degradation was identified as a pathogenic mechanism for specific MODY9 missense variants.

    Evidence Genome sequencing of affected families, CRISPR-edited iPSCs, CUT&RUN/RNA-seq in human cells; MG132 proteasome inhibitor rescue in MIN6 cells

    PMID:40614820 PMID:41475885

    Open questions at the time
    • Why human beta-cell development is only transiently impaired without PAX4 remains mechanistically unexplained
    • Whether proteasome-targeted variants can be pharmacologically rescued in vivo untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: the identity of co-repressors recruited by PAX4's repression domain; the structural basis for PAX4 DNA binding and repression; whether PAX4 can be therapeutically delivered to human alpha or delta cells for diabetes treatment; and the full scope of direct PAX4 target genes across different endocrine cell types.
  • No co-repressor complex identified
  • No crystal or cryo-EM structure of PAX4
  • No human in vivo cell-conversion study
  • Genome-wide targets not compared across alpha, beta, delta, and enteroendocrine cells

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 9 GO:0003677 DNA binding 4
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-1266738 Developmental Biology 6 R-HSA-1643685 Disease 5 R-HSA-74160 Gene expression (Transcription) 5 R-HSA-5357801 Programmed Cell Death 4 R-HSA-162582 Signal Transduction 2
Partners
ARXHNF1ANGN3NKX2-2PAX6SREBF1

Evidence

Reading pass · 35 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 Pax4 is essential for the differentiation of insulin-producing beta cells and somatostatin-producing delta cells in the mammalian pancreas; loss of Pax4 by homologous recombination results in absence of mature beta and delta cells with a concomitant increase in glucagon-producing alpha cells, indicating Pax4 directs beta/delta cell lineage fate from multipotent endocrine progenitors. Homologous recombination knockout in mice, immunohistochemistry, hormone expression analysis Nature High 9121556
1999 PAX4 functions as a transcriptional repressor; it binds a bipartite consensus DNA sequence (paired domain + homeodomain binding sites) and represses transcription through glucagon and insulin promoters in alpha-cell lines. Repressor activity maps to multiple domains including the homeodomain and carboxyl terminus, and is not solely due to competition with PAX6 for binding sites, as a GAL4-PAX4 fusion also represses via the GAL4 binding site. PCR-based selection of optimal DNA-binding sequences, GAL4 fusion reporter assays, domain deletion mapping in alpha- and beta-cell lines Molecular and cellular biology High 10567552
1999 Pax4 contains both an activation domain in its C-terminal region (active only in E1A-containing cells) and a portable repression domain that functions regardless of cell type. The repression domain abolishes the transactivation potential of the heterologous PDX-1 when fused to it, indicating Pax4 functions primarily as a transcriptional repressor whose activity is subject to posttranslational regulation. GAL4-Pax4 chimera reporter assays, domain deletion mapping, exogenous E1A expression Molecular and cellular biology High 10567553
1999 PAX4 inhibits the human insulin promoter through the C2 box element (at -253 to -244) and the islet amyloid polypeptide (IAPP) promoter through an element downstream of -138. The inhibitory activity was mapped to separate regions between amino acids 2-230 and 231-349. Promoter-reporter assays with deletion constructs in insulinoma cells FEBS letters Medium 10601637
1999 The Pax4 paired domain binds DNA with specificity similar to Pax6 paired domain despite differences at residues responsible for Pax6 specificity; the Pax4 homeodomain preferentially dimerizes on DNA consisting of inverted TAAT motifs separated by 4 nucleotides; the Pax4 C-terminal region contains the transactivation domain with lower activity than Pax6, suggesting Pax4 can act as a Pax6 repressor by competition for binding sites combined with lower transactivation. In vitro DNA binding assays, GAL-based reporter assays, cloning and sequencing Biochemical and biophysical research communications Medium 10364449
2000 The human PAX4 promoter is controlled by a 118-bp region ~1.9 kb upstream of the transcription start site that is necessary and sufficient for pancreas-specific expression; this region contains binding sites for HNF1alpha, HNF4alpha, PDX1, and a bHLH heterodimer. PAX4 itself binds at least two high-affinity sites within its own promoter and exerts strong negative autoregulation. Deletion mapping of promoter, transgenic reporter assays in mice and cell lines, site-directed mutagenesis The Journal of biological chemistry High 10967107
2003 Arx and Pax4 have opposing roles in endocrine pancreas development: loss of Arx causes loss of alpha cells with increase in beta and delta cells (opposite of Pax4 loss phenotype), and transcript levels of Pax4 accumulate in Arx mutants and vice versa, establishing that Arx and Pax4 act as transcriptional repressors that control each other's expression levels to mediate endocrine cell fate allocation. Gene targeting knockout in mice, immunohistochemistry, multiplex RT-PCR Genes & development High 14561778
2003 HNF1alpha and Neurogenin3 synergistically activate the Pax4 promoter through a short ~2 kb upstream sequence; the two factors physically interact and both activation domains are required for synergy. Exogenous Neurogenin3 is sufficient to induce endogenous Pax4 expression in cells already expressing HNF1alpha, establishing the upstream transcriptional cascade controlling Pax4 in endocrine progenitors. Promoter reporter assays, co-transfection, Co-IP demonstrating physical interaction, endogenous gene induction in mPAC and NIH3T3 cells The Journal of biological chemistry High 12837760
2003 A neuron-restrictive silencer element (NRSE)-like motif in the upstream Pax4 promoter is highly conserved, forms a DNA-protein complex with NRSF (neuron-restrictive silencer factor), and confers NRSF-dependent transcriptional repression of the Pax4 gene, placing NRSF as an upstream regulator of Pax4 expression. EMSA (gel retardation assay), promoter-reporter assays, NRSF-dependent repression demonstrated in reporter context The Journal of biological chemistry Medium 12829700
2004 During pancreas ontogeny, Pax4 is required for appropriate initiation of beta-cell differentiation: loss of Pax4 prevents expression of Pdx1, HB9, and insulin in beta-cell precursors; this role appears to be accomplished via genetic interaction with Nkx2.2, as demonstrated by epistasis analysis. Pax4 knockout mouse analysis, immunohistochemistry, genetic epistasis with Nkx2.2 Developmental biology High 14729487
2004 Pax4 overexpression in rat and human islets causes a 3.5-fold increase in beta-cell proliferation, and transactivates the Bcl-xL and c-myc promoters; increased Bcl-xL activity altered mitochondrial calcium levels and ATP production. The diabetes-linked mutant form was less efficient at transactivating these promoters. Adenoviral overexpression in rat and human islets, promoter-reporter assays (Bcl-xL, c-myc), proliferation assays, calcium and ATP measurements The Journal of cell biology High 15596543
2005 In the combined absence of Arx and Pax4, virtually all endocrine cells adopt a somatostatin-producing delta-cell fate at the expense of alpha and beta cells, revealing that both Arx and Pax4 act as transcriptional repressors that control each other's expression levels and together mediate endocrine fate allocation away from the delta-cell default. Double knockout mice (Arx/Pax4), immunohistochemistry, qRT-PCR Development (Cambridge, England) High 15930104
2006 Notch signaling activation in Pax4(+) endocrine progenitors inhibits their differentiation into alpha and beta cells and shunts them toward a duct cell fate, demonstrating that Pax4(+) progenitors are bipotent (endocrine and duct) and that Notch acts upstream of Pax4 lineage commitment. Cre-mediated conditional Notch activation in Pax4+ cells, lineage tracing, immunohistochemistry Mechanisms of development High 17196797
2006 Activin A-induced expression of PAX4 requires an E-box and HNF-1alpha binding sites ~1930 bp upstream of the transcriptional start site; activin A enhances transactivation by E47/E12 bHLH proteins without increasing their DNA binding, and siRNA knockdown of E47/E12 reduces activin A-induced PAX4 expression. Promoter-reporter assays with mutation analysis, siRNA knockdown, EMSA Biochimica et biophysica acta Medium 16546275
2007 The paired domain of Pax4 functions as a novel protein transduction domain (PTD) enabling the Pax4 protein to permeate into various cell types including pancreatic islets in a dose- and time-dependent manner; cellular uptake is blocked by heparin and partially by cytochalasin D and amiloride; transduced Pax4 protein retains function (inhibits Pax6-mediated transactivation, protects Min6 cells from TNFalpha-induced apoptosis). Protein transduction assays, heparin/cytochalasin D/amiloride blocking, reporter assays, apoptosis assays Endocrinology Medium 17717051
2007 Pax4 is essential for survival of insulinoma INS-1E cells through upregulation of the antiapoptotic gene Bcl-xL; shRNA knockdown of Pax4 reduced Bcl-xL mRNA by ~50%, increased spontaneous apoptosis twofold, and sensitized cells to cytokine-induced death, while proliferation was unaltered. shRNA adenoviral knockdown, RT-PCR, apoptosis assays Oncogene Medium 17260022
2008 Pax4 is expressed in adult rat pineal gland and retinal photoreceptors with a diurnal rhythm; nocturnal down-regulation in the pineal gland is mediated by adrenergic-cAMP signaling via sympathetic innervation (superior cervical ganglionectomy prevents nocturnal decrease; adrenergic agonists and cAMP mimics suppress Pax4 mRNA in vivo and in vitro), revealing a non-pancreatic regulatory role for Pax4. Superior cervical ganglionectomy, adrenergic agonist/cAMP treatment in vivo and in vitro, diurnal mRNA quantification, in situ hybridization Endocrinology Medium 18818287
2008 Pax4 is a transcriptional repressor of ghrelin; in Pax4-deficient mice, ghrelin-expressing cells are overabundant in the pancreas and duodenum, and lineage tracing showed these cells arose from Pax4-deficient progenitors, establishing ghrelin as a direct target gene repressed by Pax4. Pax4 knockout mice, immunohistochemistry, lineage tracing, in vitro reporter assays Developmental dynamics High 18058910
2009 Ectopic expression of Pax4 in alpha cells forces them to adopt a beta cell fate; this causes glucagon deficiency, triggering compensatory continuous glucagon+ cell neogenesis requiring Ngn3 re-expression, but newly formed alpha cells are also converted by Pax4, resulting in a cycle of neogenesis and redifferentiation that expands the beta-cell mass and can cure streptozotocin-induced diabetes. Conditional ectopic Pax4 expression using cell-specific promoters in transgenic mice, lineage tracing, immunohistochemistry, STZ-induced diabetes model Cell High 19665969
2011 Pax4 protects adult beta cells from stress-induced apoptosis by suppressing selective NF-kappaB target genes (IL-1beta), while increasing Bcl-2 expression; Pax4 also promotes dedifferentiation and proliferation through MafA repression with concomitant increases in Cdk4 and c-myc expression. The diabetes-linked mutant Pax4R129W did not convey protection and instead increased NOS2 and IL-1beta. Transgenic mice with conditional beta-cell Pax4 overexpression, STZ challenge, cytokine-treated isolated islets, cytochrome C release assay, qRT-PCR, immunohistochemistry Diabetes High 21521872
2012 Pax4 and Arx have opposing roles in enteroendocrine subtype specification: Pax4-deficient mice show impaired differentiation of serotonin and somatostatin cells and some GIP and gastrin cells, while L-cell (GLP-1) numbers increase with upregulation of Arx, mirroring the antagonistic relationship seen in the pancreas. Arx and Pax4 knockout mice, histological analysis, immunohistochemistry, lineage tracing in intestine and colon PloS one High 22570716
2015 Ectopic Pax4 expression in somatostatin-producing delta cells is sufficient to induce their conversion into functional beta-like cells; this conversion triggers compensatory mechanisms involving reactivation of endocrine developmental processes resulting in dramatic beta-like cell hyperplasia, and these beta-like cells can partly reverse chemically-induced diabetes. Transgenic mice expressing Pax4 specifically in somatostatin cells (SST-Cre), lineage tracing, immunohistochemistry, STZ-induced diabetes model The Journal of cell biology High 29025873
2016 PAX4 overexpression protects beta cells against ER stress-induced apoptosis by preserving ER homeostasis; PAX4-overexpressing islets are protected against thapsigargin-mediated ER-stress-related apoptosis, ER luminal swelling is rescued, and cytosolic calcium oscillations in response to glucose are preserved. Microarray profiling showed PAX4 regulates genes implicated in cell cycle and ER homeostasis, and the diabetes-linked PAX4R129W mutant does not confer this protection. Conditional transgenic overexpression, thapsigargin ER stress induction, electron microscopy of ER, intracellular calcium measurements, microarray profiling, RNAi knockdown Diabetologia High 26813254
2017 PAX4 acts as a transcription factor required for myofibril breakdown during muscle atrophy by denervation; PAX4 induces expression of proteolytic enzymes (including p97/VCP ATPase); down-regulation of PAX4 or its target p97/VCP reduces myofibril disassembly and protein degradation during denervation or fasting atrophy. Denervation atrophy mouse model (tibialis anterior), PAX4 knockdown, immunofluorescence, protein degradation assays, target gene expression analysis Proceedings of the National Academy of Sciences of the United States of America Medium 28096335
2018 SREBP1c directly regulates PAX4 as a target gene in pancreatic beta cells; SREBP1c activation promotes beta-cell proliferation through PAX4, and SREBP1c-deficient mice show glucose intolerance with reduced beta-cell proliferation and insulin secretion, placing SREBP1c upstream of PAX4 in the beta-cell compensatory response to metabolic stress. SREBP1c knockout and overexpression mice, qRT-PCR, islet transplantation, promoter/target gene analysis Diabetes Medium 30352876
2001 A novel variant form of PAX4 (PAX4v), generated by alternative splicing lacking exon 7 and containing intact paired and homeodomain followed by novel 35 amino acids, reverses wild-type PAX4-mediated repression of the insulin promoter in co-transfection assays, functioning as a dominant negative. Alternative splicing identification by RT-PCR, co-transfection reporter assays for dominant-negative activity Biochemical and biophysical research communications Medium 11263967
2001 A 0.9 kb DNA fragment in the 5' region of the mouse Pax4 gene is sufficient to direct Pax4 expression specifically to the endocrine pancreas in transgenic mice, recapitulating the beta-cell-specific expression pattern; this fragment contains a 407 bp region highly conserved (88% identity) between human and mouse with motifs involved in beta-cell-specific expression of insulin, Pdx1, and IAPP. Transgenic reporter mice with fragment deletions Mechanisms of development Medium 11118882
2023 PAX4 loss-of-function in human beta cells (EndoC-βH1 knockdown) impairs insulin secretion and reduces total insulin content; deletion of PAX4 in hiPSC-derived islet-like cells results in derepression of alpha cell gene expression. CUT&RUN sequencing identified PAX4-bound direct target genes involved in islet development and glucose-stimulated insulin secretion. hiPSCs carrying PAX4 risk alleles exhibit increased polyhormonal cell formation and reduced insulin content reversible by gene correction. PAX4 knockdown in EndoC-βH1 cells, CRISPR deletion in hiPSCs, CUT&RUN-sequencing, RNA-seq, insulin secretion assays, gene correction Nature communications High 37777536
2007 R164W mutation in PAX4 impairs its transcriptional repressor activity on insulin and glucagon promoters in vitro, providing a functional mechanism for its association with MODY. In vitro transcriptional repressor assay (luciferase reporter) in transfected cell lines The Journal of clinical endocrinology and metabolism Medium 17426099
2004 The Arg133Trp variant of PAX4, found in west African populations, shows decreased transcriptional repression of target gene promoters in alpha-TC1.6 cell lines, providing a functional mechanism for its association with ketosis-prone diabetes. Promoter-reporter assays in alpha-TC1.6 cells Human molecular genetics Medium 15509590
2015 PAX4 IVS7-1G>A mutation disrupts a splice acceptor site, causing use of a cryptic splice site in exon 8, resulting in a 3-nucleotide deletion and glutamine deletion at position 250 (p.Q250del); the mutant protein localizes normally to the nucleus but has significantly impaired repressor function on insulin and glucagon promoters, and increases apoptosis under high-glucose conditions. Minigene splicing assay, Western blot, nuclear localization assay, luciferase reporter assay, apoptosis assay Acta diabetologica Medium 25951767
2012 PAX4 R192H polymorphism produces a protein with defective transcriptional repressor activity on human insulin and glucagon promoters when expressed in beta- and alpha-cell lines, though protein expression and nuclear localization are equivalent to wild-type. Western blot, nuclear fractionation, dual-luciferase reporter assay in betaTC3 and alphaTC-1.9 cells Journal of diabetes and its complications Medium 22521316
2025 Homozygous PAX4 loss-of-function variants cause transient neonatal diabetes in humans; CUT&RUN-sequencing in EndoC-βH1 cells and RNA-sequencing in PAX4-depleted iPSC-derived pancreatic cells identified direct PAX4 target genes involved in islet development and glucose-stimulated insulin secretion. Unlike in mice, complete loss of PAX4 is not essential for human beta-cell development (transient rather than permanent NDM). Genome sequencing, CRISPR-editing of iPSCs, CUT&RUN-sequencing in EndoC-βH1 cells, RNA-sequencing, qPCR in pancreatic endoderm cells Molecular metabolism High 40614820
2025 Novel PAX4 frameshift variant (p.Gln28ArgfsTer6) is undetectable due to nonsense-mediated decay; missense variants p.Leu12Pro and p.Arg163Pro retain nuclear localization but are degraded by the proteasome (protein levels restored by MG132 treatment), demonstrating that enhanced proteasomal degradation is a pathogenic mechanism for certain PAX4 missense variants causing MODY9. Protein expression in MIN6 cells, nuclear localization assay, proteasome inhibitor (MG132) rescue experiment, Western blot BMJ open diabetes research & care Medium 41475885
2023 In zebrafish, Pax4 binds to the ghrelin regulatory region and represses ghrelin transcription; deletion of Pax4 derepresses ghrelin expression, expands ghrelin-expressing epsilon cells, and enhances transdifferentiation of epsilon cells to beta cells after extreme beta-cell loss. Zebrafish Pax4 deletion, NTR-mediated beta-cell ablation model, lineage tracing, ghrelin overexpression, ChIP/binding assay on ghrelin regulatory region Development (Cambridge, England) Medium 36897579

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1997 The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. Nature 657 9121556
2003 Opposing actions of Arx and Pax4 in endocrine pancreas development. Genes & development 451 14561778
2009 The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell 441 19665969
2003 Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proceedings of the National Academy of Sciences of the United States of America 324 12525695
2005 The simultaneous loss of Arx and Pax4 genes promotes a somatostatin-producing cell fate specification at the expense of the alpha- and beta-cell lineages in the mouse endocrine pancreas. Development (Cambridge, England) 175 15930104
1999 Paired-homeodomain transcription factor PAX4 acts as a transcriptional repressor in early pancreatic development. Molecular and cellular biology 150 10567552
2004 The diabetes-linked transcription factor PAX4 promotes {beta}-cell proliferation and survival in rat and human islets. The Journal of cell biology 135 15596543
2004 The concerted activities of Pax4 and Nkx2.2 are essential to initiate pancreatic beta-cell differentiation. Developmental biology 117 14729487
2007 PAX4 mutations in Thais with maturity onset diabetes of the young. The Journal of clinical endocrinology and metabolism 113 17426099
2003 Neurogenin3 and hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4. The Journal of biological chemistry 95 12837760
2004 PAX4 gene variations predispose to ketosis-prone diabetes. Human molecular genetics 91 15509590
2001 A missense mutation of Pax4 gene (R121W) is associated with type 2 diabetes in Japanese. Diabetes 90 11723072
2013 Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4. Diabetologia 79 23532257
2012 The homeodomain-containing transcription factors Arx and Pax4 control enteroendocrine subtype specification in mice. PloS one 77 22570716
2004 The gene Pax4 is an essential regulator of pancreatic beta-cell development. Molecules and cells 73 15650323
2000 Autoregulation and maturity onset diabetes of the young transcription factors control the human PAX4 promoter. The Journal of biological chemistry 69 10967107
2022 Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY. Diabetes 55 35108381
2005 Association of childhood type 1 diabetes mellitus with a variant of PAX4: possible link to beta cell regenerative capacity. Diabetologia 55 15834548
2017 Myofibril breakdown during atrophy is a delayed response requiring the transcription factor PAX4 and desmin depolymerization. Proceedings of the National Academy of Sciences of the United States of America 53 28096335
1999 Identification of a portable repression domain and an E1A-responsive activation domain in Pax4: a possible role of Pax4 as a transcriptional repressor in the pancreas. Molecular and cellular biology 53 10567553
2008 Developmental and diurnal dynamics of Pax4 expression in the mammalian pineal gland: nocturnal down-regulation is mediated by adrenergic-cyclic adenosine 3',5'-monophosphate signaling. Endocrinology 50 18818287
2015 PAX4 Gene Transfer Induces α-to-β Cell Phenotypic Conversion and Confers Therapeutic Benefits for Diabetes Treatment. Molecular therapy : the journal of the American Society of Gene Therapy 49 26435408
2006 Notch signaling reveals developmental plasticity of Pax4(+) pancreatic endocrine progenitors and shunts them to a duct fate. Mechanisms of development 49 17196797
2015 Pax4 acts as a key player in pancreas development and plasticity. Seminars in cell & developmental biology 48 26319183
2014 Transcriptional control of PAX4-regulated miR-144/451 modulates metastasis by suppressing ADAMs expression. Oncogene 46 25151965
2008 Ghrelin is a novel target of Pax4 in endocrine progenitors of the pancreas and duodenum. Developmental dynamics : an official publication of the American Association of Anatomists 46 18058910
2007 The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1. Human molecular genetics 46 17989064
2008 A focus on the role of Pax4 in mature pancreatic islet beta-cell expansion and survival in health and disease. Journal of molecular endocrinology 45 18234907
2017 The Diabetes-Linked Transcription Factor PAX4: From Gene to Functional Consequences. Genes 40 28282933
2011 In vivo conditional Pax4 overexpression in mature islet β-cells prevents stress-induced hyperglycemia in mice. Diabetes 40 21521872
2018 Nonsynonymous Variants in PAX4 and GLP1R Are Associated With Type 2 Diabetes in an East Asian Population. Diabetes 38 29941447
2016 PAX4 preserves endoplasmic reticulum integrity preventing beta cell degeneration in a mouse model of type 1 diabetes mellitus. Diabetologia 37 26813254
2011 A novel PAX4 mutation in a Japanese patient with maturity-onset diabetes of the young. The Tohoku journal of experimental medicine 37 21263211
2008 PAX4 enhances beta-cell differentiation of human embryonic stem cells. PloS one 37 18335054
2008 Developmental and daily expression of the Pax4 and Pax6 homeobox genes in the rat retina: localization of Pax4 in photoreceptor cells. Journal of neurochemistry 37 19012751
2015 PAX4 Defines an Expandable β-Cell Subpopulation in the Adult Pancreatic Islet. Scientific reports 35 26503027
2007 The transcription factor PAX4 acts as a survival gene in INS-1E insulinoma cells. Oncogene 35 17260022
2002 Beta-cell dysfunction in late-onset diabetic subjects carrying homozygous mutation in transcription factors NeuroD1 and Pax4. Metabolism: clinical and experimental 35 12200761
2001 Pax4 regulatory elements mediate beta cell specific expression in the pancreas. Mechanisms of development 35 11118882
1999 Inhibitory effect of pax4 on the human insulin and islet amyloid polypeptide (IAPP) promoters. FEBS letters 35 10601637
2023 PAX4 loss of function increases diabetes risk by altering human pancreatic endocrine cell development. Nature communications 32 37777536
2006 Role of Pax4 in Pdx1-VP16-mediated liver-to-endocrine pancreas transdifferentiation. Laboratory investigation; a journal of technical methods and pathology 32 16732298
1999 No evidence of linkage or diabetes-associated mutations in the transcription factors BETA2/NEUROD1 and PAX4 in Type II diabetes in France. Diabetologia 31 10230653
2017 Ectopic expression of Pax4 in pancreatic δ cells results in β-like cell neogenesis. The Journal of cell biology 29 29025873
2011 Streptozotocin-induced expression of Ngn3 and Pax4 in neonatal rat pancreatic α-cells. World journal of gastroenterology 28 21734788
2015 Aberrant mRNA splicing of paired box 4 (PAX4) IVS7-1G>A mutation causing maturity-onset diabetes of the young, type 9. Acta diabetologica 26 25951767
2001 Expression of dominant negative form of PAX4 in human insulinoma. Biochemical and biophysical research communications 26 11263967
2003 Regulation of Pax4 paired homeodomain gene by neuron-restrictive silencer factor. The Journal of biological chemistry 25 12829700
2012 Defective PAX4 R192H transcriptional repressor activities associated with maturity onset diabetes of the young and early onset-age of type 2 diabetes. Journal of diabetes and its complications 23 22521316
2007 Enhancement of insulin-producing cell differentiation from embryonic stem cells using pax4-nucleofection method. World journal of gastroenterology 23 17461469
2007 Pax4 paired domain mediates direct protein transduction into mammalian cells. Endocrinology 23 17717051
1999 DNA binding and transactivating properties of the paired and homeobox protein Pax4. Biochemical and biophysical research communications 22 10364449
2006 The Arg121Trp variant in PAX4 gene is associated with beta-cell dysfunction in Japanese subjects with type 2 diabetes mellitus. Metabolism: clinical and experimental 21 16423628
1998 Isolation of full-length cDNA of mouse PAX4 gene and identification of its human homologue. Biochemical and biophysical research communications 21 9480859
2014 Evolution of the vertebrate Pax4/6 class of genes with focus on its novel member, the Pax10 gene. Genome biology and evolution 20 24951566
2014 Overexpression of PAX4 reduces glucagon expression in differentiating hESCs. Islets 20 25483960
2013 Both PAX4 and MAFA are expressed in a substantial proportion of normal human pancreatic alpha cells and deregulated in patients with type 2 diabetes. PloS one 20 24013263
2021 A nexus of miR-1271, PAX4 and ALK/RYK influences the cytoskeletal architectures in Alzheimer's Disease and Type 2 Diabetes. The Biochemical journal 19 34409981
2018 SREBP1c-PAX4 Axis Mediates Pancreatic β-Cell Compensatory Responses Upon Metabolic Stress. Diabetes 19 30352876
2016 Exome-chip association analysis reveals an Asian-specific missense variant in PAX4 associated with type 2 diabetes in Chinese individuals. Diabetologia 19 27744525
2018 Generation and Phenotype Identification of PAX4 Gene Knockout Rabbit by CRISPR/Cas9 System. G3 (Bethesda, Md.) 18 29950431
2017 PAX4 promotes PDX1-induced differentiation of mesenchymal stem cells into insulin-secreting cells. American journal of translational research 17 28386318
2016 PAX4 R192H and P321H polymorphisms in type 2 diabetes and their functional defects. Journal of human genetics 17 27334367
2008 PAX4 has the potential to function as a tumor suppressor in human melanoma. International journal of oncology 17 18949370
1998 Organisation of the human PAX4 gene and its exclusion as a candidate for the Wolcott-Rallison syndrome. Journal of medical genetics 17 9598721
2011 Co-orthology of Pax4 and Pax6 to the fly eyeless gene: molecular phylogenetic, comparative genomic, and embryological analyses. Evolution & development 15 23016906
2003 PAX4 mutation (R121W) as a prodiabetic variant in Okinawans. Biochemical and biophysical research communications 15 12604352
1994 Assignment of the human PAX4 gene to chromosome band 7q32 by fluorescence in situ hybridization. Cytogenetics and cell genetics 15 8287686
2000 Cloning of the mouse Pax4 gene promoter and identification of a pancreatic beta cell specific enhancer. Molecular and cellular endocrinology 14 11162892
2019 Pax4 synergistically acts with Pdx1, Ngn3 and MafA to induce HuMSCs to differentiate into functional pancreatic β-cells. Experimental and therapeutic medicine 13 31572507
2018 Therapeutic potential of pancreatic PAX4-regulated pathways in treating diabetes mellitus. Current opinion in pharmacology 13 30048825
2014 Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients. The pharmacogenomics journal 13 24752311
2006 Aberrant DNA demethylation in promoter region and aberrant expression of mRNA of PAX4 gene in hematologic malignancies. Leukemia research 13 16701883
1998 Molecular cloning of rat Pax4: identification of four isoforms in rat insulinoma cells. Biochemical and biophysical research communications 13 9675102
2023 Pax4 in Health and Diabetes. International journal of molecular sciences 12 37175989
2005 Lack of association of PAX4 gene with type 1 diabetes in the Finnish and Hungarian populations. Diabetes 11 16123375
1998 Molecular cloning of mouse paired-box-containing gene (Pax)-4 from an islet beta cell line and deduced sequence of human Pax-4. Biochemical and biophysical research communications 11 9439631
2022 C.487C>T mutation in PAX4 gene causes MODY9: A case report and literature review. Medicine 10 36595822
2020 Identification of the First PAX4-MODY Family Reported in Brazil. Diabetes, metabolic syndrome and obesity : targets and therapy 10 32801813
2003 DNA sequence motifs conserved in endocrine promoters are essential for Pax4 expression. Developmental dynamics : an official publication of the American Association of Anatomists 9 14648838
2023 Pax4-Ghrelin mediates the conversion of pancreatic ε-cells to β-cells after extreme β-cell loss in zebrafish. Development (Cambridge, England) 8 36897579
2020 Pax4 Gene Delivery Improves Islet Transplantation Efficacy by Promoting β Cell Survival and α-to-β Cell Transdifferentiation. Cell transplantation 8 33086892
2008 The association of the PAX4 gene with type 1 diabetes in Han Chinese. Diabetes research and clinical practice 8 18617287
2021 Transcription factor PAX4 facilitates gastric cancer progression through interacting with miR-27b-3p/Grb2 axis. Aging 7 34162761
2018 PAX4 R192H is associated with younger onset of Type 2 diabetes in East Asians in Singapore. Journal of diabetes and its complications 6 30528630
2006 Activin A-induced expression of PAX4 in AR42J-B13 cells involves the increase in transactivation of E47/E12. Biochimica et biophysica acta 6 16546275
2022 Conversion of Gastrointestinal Somatostatin-Expressing D Cells Into Insulin-Producing Beta-Like Cells Upon Pax4 Misexpression. Frontiers in endocrinology 5 35573999
2020 Missense Variants in PAX4 Are Associated with Early-Onset Diabetes in Chinese. Diabetes therapy : research, treatment and education of diabetes and related disorders 5 33216280
2017 Improved insulin-secreting properties of pancreatic islet mesenchymal stem cells by constitutive expression of Pax4 and MafA. Turkish journal of biology = Turk biyoloji dergisi 5 30814862
2015 Pax4 Expression does not Transduce Pancreatic Alpha Cells to Beta Cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 5 26183751
2012 Generation of animals allowing the conditional inactivation of the Pax4 gene. Transgenic research 4 22717987
2009 No association of the IRS1 and PAX4 genes with type I diabetes. Genes and immunity 4 19956100
2000 IFN-gamma overexpression within the pancreas is not sufficient to rescue Pax4, Pax6, and Pdx-1 mutant mice from death. Pancreas 4 11075995
2022 The Roles of Different Multigene Combinations of Pdx1, Ngn3, Sox9, Pax4, and Nkx2.2 in the Reprogramming of Canine ADSCs Into IPCs. Cell transplantation 3 35236160
2022 Ethnic-Specific Type 2 Diabetes Risk Factor PAX4 R192H Is Associated with Attention-Specific Cognitive Impairment in Chinese with Type 2 Diabetes. Journal of Alzheimer's disease : JAD 2 35570489
2007 [Association between A1168C polymorphism in PAX4 gene and type 1 diabetes in Han Chinese]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2 17633464
2024 PAX4 gene delivery improves β-cell function in human islets of Type II diabetes. Regenerative medicine 1 39118533
2020 [Alternative Variants of Pax4 Human Transcription Factor: Comparative Transcriptional Activity]. Molekuliarnaia biologiia 1 33009794
2025 Complete loss of PAX4 causes transient neonatal diabetes in humans. Molecular metabolism 0 40614820
2025 dentification and characterization of novel PAX4 variants in patients with suspected MODY9. BMJ open diabetes research & care 0 41475885